Methods and compositions for treating a cell-proliferative disorder using CRE decoy oligomers, BCL-2 antisense oligomers, and hybrid oligomers thereof
The present invention is directed to hybrid oligomers comprising a cyclic AMP response element (CRE) sequence and a sequence that hybridizes to a bcl-2 pre-mRNA or mRNA, and pharmaceutical compositions comprising such hybrids. The present invention is also directed to the use of CRE decoy oligomers, comprising a CRE consensus sequence, and bcl-2 antisense oligomers in combination therapies, and the use of bcl-2/CRE hybrid oligomers, to treat or prevent cell-proliferative related disorders, including hyperplasias, cancers, tumors and carcinomas. In one embodiment, the invention relates to therapeutic protocols comprising the administration of a CRE decoy oligomer and a bcl-2 antisense oligomer for the treatment of cell-proliferative related disorders. In another embodiment, the invention relates to therapeutic protocols comprising the administration of a bcl-2 antisense/CRE decoy (bcl-2/CRE) hybrid oligomer for the treatment of cell-proliferative related disorders.
1. A hybrid oligonucleotide comprising a CRE sequence and a sequence that hybridizes to a bcl-2 pre-mRNA or mRNA.
2. The hybrid oligonucleotide of claim 1 , wherein the sequence which hybridizes to the bcl-2 pre-mRNA or mRNA comprises at least 10 consecutive bases that are complementary to the bcl-2 pre-mRNA or mRNA.
3. The hybrid oligonucleotide of claim 1 , wherein the sequence that hybridizes to the bcl-2 pre-mRNA or mRNA comprises 5′-TCTCCCAGCG-3′ (SEQ ID NO:35).
4. The hybrid oligonucleotide of claim 1 , wherein the CRE sequence comprises 5′-TGACGTCA-3′.
5. The hybrid oligonucleotide of claim 4 , further comprising the sequence 5′-TCTCCCAGCG-3′ (SEQ ID NO:35).
6. The hybrid oligonucleotide of claim 1 , wherein the CRE sequence is linked to the sequence that hybridizes to the bcl-2 pre-mRNA or mRNA.
7. The hybrid oligonucleotide of claim 6 , wherein the CRE sequence comprises two or more CRE consensus sequences.
8. The hybrid oligonucleotide of claim 7 , wherein a first CRE consensus sequence is linked to a second CRE consensus sequence by one or more bases.
9. A method of inhibiting the growth of cancer cells in vitro comprising contacting the cancer cells with a hybrid oligonucleotide comprising a CRE sequence and a sequence that hybridizes to a bcl-2 pre-mRNA or mRNA.
10. The method of claim 9 , wherein the sequence which hybridizes to the bcl-2 pre-mRNA or mRNA comprises at least 10 consecutive bases that are complementary to the bcl-2 pre-mRNA or mRNA.
11. The method of claim 9 , wherein the sequence that hybridizes to the bcl-2 pre-mRNA or mRNA comprises 5′-TCTCCCAGCG-3′ (SEQ ID NO:35).
12. The method of claim 9 , wherein the CRE sequence comprises 5′-TGACGTCA-3′.
13. The method of claim 12 , wherein the hybrid oligonucleotide further comprises the sequence 5′-TCTCCCAGCG-3′ (SEQ ID NO:35).
14. The method of claim 9 , wherein the CRE sequence is linked to the sequence that hybridizes to the bcl-2 pre-mRNA or mRNA.
15. The method of claim 14 , wherein the CRE sequence comprises two or more CRE consensus sequences.
16. The method of claim 15 , wherein a first CRE consensus sequence is linked to a second CRE consensus sequence by one or more bases.
17. The method of claim 9 , further comprising contacting the cancer cells with a bcl-2 antisense oligonucleotide.
18. The method of claim 9 , further comprising contacting the cancer cells with a CRE decoy oligonucleotide.
19. The method of claim 9 , further comprising contacting the cancer cells with a bcl-2 antisense oligonucleotide and a CRE decoy oligonucleotide.
20. The method of claim 9 , further comprising contacting the cancer cells with one or more cancer therapeutic agents.
21. A method of treating cancer in a human comprising administering to said human, in which such treatment is desired, a hybrid oligonucleotide comprising a CRE sequence and a sequence that hybridizes to the bcl-2 pre-mRNA or mRNA.
22. The method of claim 21 , wherein the sequence, which hybridizes to the bcl-2 pre-mRNA or mRNA comprises at least 10 consecutive bases that are complementary to the bcl-2 pre-mRNA or mRNA.
23. The method of claim 21 , wherein the sequence that hybridizes to the bcl-2 pre-mRNA or mRNA comprises 5′-TCTCCCAGCG-3′ (SEQ ID NO:35).
24. The method of claim 21 , wherein the CRE sequence comprises 5′-TGACGTCA-3′.
25. The method of claim 24 , wherein the hybrid oligonucleotide further comprises the sequence 5′-TCTCCCAGCG-3′ (SEQ ID NO:35).
26. The method of claim 21 , wherein the CRE sequence is linked to the sequence that hybridizes to the bcl-2 pre-mRNA or mRNA.
27. The method of claim 26 , wherein the CRE sequence comprises two or more CRE consensus sequences.
28. The method of claim 27 , wherein a first CRE consensus sequence is linked to a second CRE consensus sequence by one or more bases.
29. The method of claim 21 , further comprising administering a bcl-2 antisense oligonucleotide.
30. The method of claim 21 , further comprising administering a CRE decoy oligonucleotide.
31. The method of claim 21 , further comprising administering a bcl-2 antisense oligonucleotide and a CRE decoy oligonucleotide.
32. The method of claim 31 , further comprising administering one or more cancer therapeutic agents.
33. The method of claim 32 , wherein administration of the cancer therapeutic agent follows administration of the bcl-2 antisense oligonucleotide and the CRE decoy oligonucleotide.
34. The method of claim 32 , wherein administration of the cancer therapeutic agent precedes administration of the bcl-2 antisense oligonucleotide and the CRE decoy oligonucleotide.
35. The method of claim 32 , wherein the cancer therapeutic agent is administered concurrently with the bcl-2 antisense oligonucleotide and the CRE decoy oligonucleotide.
36. The method of claim 32 , wherein said cancer therapeutic agent is a chemoagent, radiotherapeutic, immunotherapeutic, cancer vaccine, anti-angiogenic agent, cytokine, gene therapeutic, or hormonal agent.
37. The method of claim 32 , wherein said cancer therapeutic agent is a chemoagent, and wherein said chemoagent is dacarbazine, docetaxel, paclitaxel, cisplatin, 5-fluorouracil, doxorubicin, etoposide, cyclophosphamide, fludarabine, irinotecan, or cytosine arabinoside (Ara-C).
38. The method of claim 32 , wherein said cancer therapeutic agent is administered at a reduced dose.
39. The method of claim 21 , wherein said administration is by oral, intravenous infusion, subcutaneous injection, intramuscular injection, topical, depo injection, implantation, time-release mode, intracavitary, intranasal, inhalation, intratumor, or intraocular administration.
40. The method of claim 21 , wherein the hybrid oligonucleotide is administered for a period consisting of 2 to 13 days.
41. The method of claim 21 , wherein the hybrid oligonucleotide is administered for a period consisting of 14 to 28 days.
42. The method of claim 21 , comprising administering 0.01 to 10 mg/kg/day of the hybrid oligonucleotide.
43. The method of claim 21 , comprising administering 10 to 50mg/kg/day of the hybrid oligonucleotide.
44. A pharmaceutical composition comprising a hybrid oligonucleotide comprising a CRE sequence and a sequence that hybridizes to a bcl-2 pre-mRNA or mRNA; and a pharmaceutically acceptable carrier.
45. The pharmaceutical composition of claim 44 further comprising a bcl-2 antisense oligonucleotide.
46. The pharmaceutical composition of claim 44 further comprising a CRE decoy oligonucleotide.
47. The pharmaceutical composition of claim 44 further comprising a bcl-2 antisense oligonucleotide a CRE decoy oligonucleotide.
48. A pharmaceutical composition comprising a CRE decoy oligonucleotide and a bcl-2 antisense oligonucleotide; and a pharmaceutically acceptable carrier.